Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Discontinuing tumour necrosis factor inhibitors in non-radiographic axial spondyloarthritis

Patients with axial spondyloarthritis are classified according to the 2009 Assessment of SpondyloArthritis international Society classification criteria—which are the basis for the differentiation between the classical ankylosing spondylitis or radiographic axial spondyloarthritis and non-radiographic axial spondyloarthritis—on the basis of the presence or absence of definite radiographic changes in the sacroiliac joints.1 Although the clinical significance of this difference has been challenged,2 the two subsets have been accepted by the European Medicines Agency, which has led to the approval of biologicals for non-radiographic axial spondyloarthritis in Europe but not in the USA to date.

email